Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Chartwell Pharmaceuticals LLC
EIR
•Chartwell Pharmaceuticals LLC•November 1, 2016

Chartwell Pharmaceuticals LLC – FDA EIR, Nov 1, 2016

Record Details

An FDA inspection of Chartwell Pharmaceuticals LLC and Chartwell Life Sciences LLC, conducted from October 27 to November 1, 2016, identified significant non-compliance with post-marketing adverse drug experience (ADE) reporting requirements. The inspection, guided by 21 CFR 314.80(c)(1)(i) and FDA's Post Marketing Adverse Drug Experience Reporting Inspections framework, revealed that the company failed to report serious and unexpected ADEs to the FDA within the mandated 15-calendar day timeframe. The core issue was an incorrect interpretation of the "aware date," where Chartwell considered the date it was notified by its distributors as the start of the reporting clock, rather than the actual date the distributor first received the adverse event information. This led to systemic delays in submitting crucial safety data to the FDA, as evidenced by multiple cited case reports. Additionally, deficiencies were noted in the reconciliation activities between Chartwell, its pharmacovigilance provider, and marketing partners, which were not consistently performed or adequately documented. Chartwell's management committed to providing a written response within 15 days. Required actions include correcting the "aware date" definition, updating written procedures and agreements to ensure timely reporting and consistent reconciliation processes, and investigating late reports to implement corrective and preventive measures.

Company
Chartwell Pharmaceuticals LLC
Inspection date
November 1, 2016
Product type
Drugs
Office
Office of Compliance
People
  • Helen B. Ricalde (Director, Team Biologics Staff)
  • Kimberly A. Ezdebski (company_representative)
View Company Profile

ID · 10f0c1e9-8bf5-4caf-9779-dad27ca98df7

Violation Codes2
21 CFR 820.19821 CFR 314.80(c)(1)(i)

Full citation text and observation details available on the Dashboard.

Other documents for Chartwell Pharmaceuticals LLC
  • 483 - 2024-12-19December 19, 2024
  • 483 - 2024-05-31May 31, 2024
  • 483 - 2023-05-24May 24, 2023
  • EIR - 2018-09-26September 26, 2018
  • 483 - 2018-09-26September 26, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Chartwell Pharmaceuticals LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.